image
Gain Therapeutics, Inc. GANX
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 1.69
3.36 %
$ 50.6 M
Market Cap
-2.04
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one GANX stock under the worst case scenario is HIDDEN Compared to the current market price of 1.69 USD, Gain Therapeutics, Inc. is HIDDEN

GANX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one GANX stock under the base case scenario is HIDDEN Compared to the current market price of 1.69 USD, Gain Therapeutics, Inc. is HIDDEN

GANX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one GANX stock under the best case scenario is HIDDEN Compared to the current market price of 1.69 USD, Gain Therapeutics, Inc. is HIDDEN

GANX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart GANX

image
1M -5%
6M -40%
1Y 40%
3Y -149%
5Y --%
All
$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.415 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-20.4 M OPERATING INCOME
8.55%
Growth Rates
1Year 8.55%
3Years -13.75%
5Years -57.50%
7Years 0.00%
10Years 0.00%
-20.4 M NET INCOME
8.34%
Growth Rates
1Year 8.34%
3Years -13.69%
5Years -56.22%
7Years 0.00%
10Years 0.00%
-18.9 M OPERATING CASH FLOW
-0.04%
Growth Rates
1Year -0.04%
3Years -15.14%
5Years -58.81%
7Years 0.00%
10Years 0.00%
4.98 M INVESTING CASH FLOW
-51.31%
Growth Rates
1Year -51.31%
3Years 279.91%
5Years 225.38%
7Years 0.00%
10Years 0.00%
13 M FINANCING CASH FLOW
2.93%
Growth Rates
1Year 2.93%
3Years -32.21%
5Years 49.34%
7Years 0.00%
10Years 0.00%
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-4.37 M OPERATING INCOME
-31.17%
Growth Rates
1Year 8.55%
3Years -13.75%
5Years -57.50%
7Years 0.00%
10Years 0.00%
-4.53 M NET INCOME
-20.22%
Growth Rates
1Year 8.34%
3Years -13.69%
5Years -56.22%
7Years 0.00%
10Years 0.00%
-3.82 M OPERATING CASH FLOW
-10.62%
Growth Rates
1Year -0.04%
3Years -15.14%
5Years -58.81%
7Years 0.00%
10Years 0.00%
0 INVESTING CASH FLOW
100.00%
Growth Rates
1Year -51.31%
3Years 279.91%
5Years 225.38%
7Years 0.00%
10Years 0.00%
2.4 M FINANCING CASH FLOW
3.64%
Growth Rates
1Year 2.93%
3Years -32.21%
5Years 49.34%
7Years 0.00%
10Years 0.00%
Balance Sheet Gain Therapeutics, Inc.
image
Current Assets 11.6 M
Cash & Short-Term Investments 10.4 M
Receivables 766 K
Other Current Assets 451 K
Non-Current Assets 521 K
Long-Term Investments 0
PP&E 323 K
Other Non-Current Assets 198 K
85.66 %6.32 %3.72 %Total Assets$12.1m
Current Liabilities 3.91 M
Accounts Payable 946 K
Short-Term Debt 271 K
Other Current Liabilities 2.69 M
Non-Current Liabilities 873 K
Long-Term Debt 382 K
Other Non-Current Liabilities 491 K
19.78 %5.67 %56.31 %7.98 %10.26 %Total Liabilities$4.8m
EFFICIENCY
Earnings Waterfall Gain Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 84.1 K
Gross Profit -84.1 K
Operating Expenses 20.4 M
Operating Income -20.4 M
Other Expenses 60.6 K
Net Income -20.4 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)0(84k)(84k)(20m)(20m)(61k)(20m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
Averages
1Year 0.00%
3Years 2.84%
5Years -2391.21%
7Years -1708.01%
10Years 0.00%
0.00% OPERATING MARGIN
0.00%
Averages
1Year 0.00%
3Years -17672.12%
5Years -14688.74%
7Years -11931.18%
10Years 0.00%
0.00% NET MARGIN
0.00%
Averages
1Year 0.00%
3Years -17636.49%
5Years -14743.20%
7Years -12055.89%
10Years 0.00%
-278.10% ROE
-278.10%
Averages
1Year -278.10%
3Years -182.77%
5Years -129.18%
7Years -6.01%
10Years 0.00%
-168.36% ROA
-168.36%
Averages
1Year -168.36%
3Years -120.34%
5Years -86.78%
7Years -128.90%
10Years 0.00%
-246.36% ROIC
-246.36%
Averages
1Year -246.36%
3Years -164.59%
5Years -115.41%
7Years 136.41%
10Years 0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Gain Therapeutics, Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)(18m)(18m)(20m)(20m)20192019202020202021202120222022202320232024202420252025
Net Income -20.4 M
Depreciation & Amortization 84.1 K
Capital Expenditures -22.5 K
Stock-Based Compensation 2.39 M
Change in Working Capital -1.08 M
Others -1.21 M
Free Cash Flow -18.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Gain Therapeutics, Inc.
image
GANX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Gain Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
64.5 K USD 2
9-12 MONTHS
7. News
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation As of June 30 th , 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 globenewswire.com - 2 weeks ago
Gain Therapeutics to Participate in Upcoming Investor Conferences BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C. globenewswire.com - 1 month ago
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the GBA1 Meeting 2025, being held June 5th-7th in Montreal, Canada. globenewswire.com - 1 month ago
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025 First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025 globenewswire.com - 2 months ago
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity globenewswire.com - 2 months ago
Gain Therapeutics to Participate at The Citizens Life Sciences Conference BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens Life Sciences Conference, being held May 7th-8th in New York City, NY. globenewswire.com - 2 months ago
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY. globenewswire.com - 2 months ago
Gain Therapeutics Announces Poster Presentation at AD/PD 2025 BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the design of the Phase 1b clinical trial of GT-02287 in Parkinson's disease will be presented at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria. globenewswire.com - 3 months ago
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025 First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025 globenewswire.com - 3 months ago
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the dosing of the first participant with Parkinson's disease (PD) in its Phase 1b clinical trial of GT-02287, the Company's lead allosteric small molecule in development for the treatment of PD with or without a GBA1 mutation. globenewswire.com - 4 months ago
Gain Therapeutics Announces Oral Presentation at AD/PD 2025 BETHESDA, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Joanne Taylor, Ph.D., Senior Vice President of Research at Gain, will give an oral presentation on the Company's clinical stage lead drug candidate GT-02287 at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria. globenewswire.com - 4 months ago
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update BETHESDA, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided the following letter to shareholders from the Company's President and CEO, Gene Mack: globenewswire.com - 5 months ago
8. Profile Summary

Gain Therapeutics, Inc. GANX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 50.6 M
Dividend Yield 0.00%
Description Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Contact 4800 Montgomery Lane, Bethesda, MD, 20814 https://www.gaintherapeutics.com
IPO Date March 19, 2021
Employees 23
Officers Mr. Gene Mack M.B.A. President, Chief Executive Officer & Director Mr. Gianluca Fuggetta Senior Vice President of Finance & Principal Financial Officer Dr. Terenzio Ignoni Pharm.D. Senior Vice President of Technical Operations Dr. Joanne Taylor Ph.D. Senior Vice President of Research Dr. Khalid Islam Ph.D. Chairman & Founder Dr. Jonas Hannestad M.D., Ph.D. Chief Medical Officer